Introduction
Antibody-based cancer therapies have been successful in several clinical trials with select groups of patients. 1, 2 The promise of these therapies lies with the potential for a high degree of specificity in targeting malignant cells through specific antigenic determinants. Antibodies alone have limited cytotoxic effects on tumor cells, so successful use of this approach requires combination treatment with conventional chemotherapies (e.g. Rituxan þ CHOP (cyclophosamide, doxorubicin, vincristine, prednisone) in non-Hodgkin's lymphoma or Herceptin þ taxol for breast cancer). 3 Alternatively, the antibodies can be conjugated to cytotoxic molecules such as calicheamicin as is the case of Mylotarg, targeting CD33, or radioactive moieties as is common with the aCD20 monoclonal antibodies (MoAbs) such as Zevalin or Bexxar. 3 The Insulin-like growth factor-1 receptor (IGF-1R) and epidermal growth factor recetpor (EGFR) are good candidates for specific antibody therapies because (1) these receptors are often overexpressed on the surface of malignant cells of diverse types and (2) inhibition of these pathways through the use of small molecule inhibitors or blocking antibodies is often cytotoxic alone. [4] [5] [6] [7] [8] Insulin-like growth factor-1 (IGF-1) is produced primarily by the liver and bone marrow stromal cells in response to pituitary growth hormones. [9] [10] [11] This small anabolic protein of 6-8 kDa is found in serum between 10 and 100 nmol/l and functions to stimulate a variety of metabolic processes. 9 Insulin-like growth factor-1 is regulated by a family of IGF-binding proteins that control its availability. For example, free IGF-1 in serum has a half-life of about 10-12 min, but IGF-1 bound to IGF-binding proteins, which accounts for nearly 90% of IGF-1, can have a half life of up to 12-15 h. 10 Insulin-like growth factor-1 receptor is found on nearly every cell type examined and are widely believed to be overexpressed on most malignant cells, although recent studies have reported that the level of detectable surface expression of IGF-1R can vary widely among normal and transformed cell types. 12, 13 Insulin-like growth factor receptor-1 can also be activated in response to insulin as well as IGF-1, although nearly 100-fold more ligand is required for response to insulin. 9 Insulin-like growth factor receptor-1 consists of two alpha and two beta subunits. 10 The alpha-subunit is involved in ligand binding and is found extracellularly. The beta-subunit spans the cell membrane and contains a tyrosine kinase domain in the cytoplasmic region.
Insulin-like growth factor-1 receptor is perhaps best known for its putative role in the growth of solid tumors. Expression of IGF-1 has been documented in prostate, lung, colon, breast, renal, thyroid and adrenal cancers, as well as in retinoblastoma and sarcoma. 4 High levels of IGF-1 appear to correlate with an increased risk of solid tumor development. Insulin-like growth factor receptor-1 pathway activation can play a role in transformation by promoting proliferation, metastasis and angiogenesis in solid tumors. 11, 12 Interestingly, primary samples from solid tumors and multiple myeloma cells have exhibited the highest sensitivity to inhibition of IGF-1R signaling. 4 Insulin-like growth factor-1 receptor has been reported to have increased expression in multiple myeloma. 14, 15 One study reported that 73% of multiple myeloma patients exhibited significantly higher levels of IGF-1R expression than that observed in 43% of normal bone marrow plasma cells. 15 Interestingly, tonsil-derived plasma cells did not express IGF-1R, suggesting that IGF-1R expression was related to bone marrow localization, where bone marrow stromal cells are known to produce IGF-1. A correlation between decreased patient survival and the presence of the 14q32 abnormality and increased IGF-1R expression in multiple myeloma cells has also been reported. 15 However, while other studies have confirmed increased expression of IGF-1R in multiple myeloma, association with disease subsets or outcome has not been confirmed. 4 Treatment of multiple myeloma cells with small molecular weight inhibitors of IGF-1R abrogated tumor growth both in xenograph models and in the stromal cell co-cultures, 4 indicating that the IGF-1R pathway is a valid therapeutic target for a disease that has few effective treatments.
In the present study, we have made use of a unique hematopoietic model for studying IGF-1R signaling to investigate the mechanism of cellular toxicity in response to an aIGF-1R antibody (A12). 6, 7 In this system, the parental interleukin (IL)-3-dependent FDC-P1 has been engineered to be IL-3 independent in the presence of IGF-1 or insulin through retroviral transduction with the IGF-1R (FD/IGF-1R). 16 Herein, we report that aIGF-1R A12 is capable of arresting FD/IGF-1R proliferation in the G1 phase of the cell cycle and induces apoptosis in the presence of IGF-1 or insulin in a mechanism involving degradation of IGF-1R protein and loss of Akt phosphorylation. Small molecule inhibitors of signaling pathways synergized with aIGF-1R treatment to induce FD/IGF-1R-mediated apoptosis with several log-lower doses of antibody and inhibitor. Our results provide mechanistic data regarding the use of IGF-1R MoAb and inhibitors of the Raf/MEK/ERK and PI3K/Akt/mTOR pathways to suppress the growth of transformed cells that proliferate in response to abnormal IGF-1R signaling.
Materials and methods

Cell culture
The generation and characterization of FD/IGF-1R cells has been described previously. 16 Cells were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA) and 5 ng/ml recombinant IL-3 in a 10% CO 2 incubator. In some instances, IGF-1 at 100 nM or insulin at 1 mM concentration was used in place of IL-3 with the FD/IGF-1R cell line. FD/IGF-1R cells require IGF-1 or insulin for growth in the absence of exogenous IL-3. 16 Some subclones will grow in the absence of IGF-1 or insulin, but these subclones express higher levels of IGF-1R and they proliferate in response to the low levels of IGF-1 present in the FBS. 16 
IGF-1R antibody treatment
The aIGF-1R antibody, A12, has been described elsewhere. 6, 7 Cells were treated with aIGF-1R for 24-48 h (unless indicated otherwise) at the indicated concentrations before analysis.
Western blotting
Cells were lysed in Gold's lysis buffer in the presence of protease inhibitors as described previously. 16 Twenty micrograms of whole-cell lysate was separated on 10% SDSpolyacrylamide gel electrophoresis gels with a 5% stacking gel, followed by transfer to polyvinylidine difluoride membranes. Blots were blocked overnight at 41C in 1 Â TBST (Tris, Borate, Salt, Tween) containing 1% bovine serum albumin (BSA). Filters were incubated with a 1:500 dilution of primary antibody overnight under the same conditions. Blots were incubated with secondary antibody and washed in 1 Â TBST, followed by chemiluminescence. Antibodies were purchased from Cell Signaling Technologies (Beverly, MA, USA).
Inhibitor treatment
U0126 was purchased from Promega (Madison, WI, USA). Rapamycin was purchased from Sigma (St Louis, MO, USA). LY294002 was obtained from Calbiochem (EMD Biosciences, La Jolla, CA, USA). Inhibitors were resuspended in dimethylsulfoxide (DMSO) as a vehicle. Dimethylsulfoxide was used as a control for vehicle effects. Inhibitors were titrated to determine the lowest dose for use in subsequent experiments that resulted in specific kinase inhibition and induction of apoptosis.
AnnexinV/PI staining
About one million cells were washed twice with phosphatebuffered saline (PBS) and stained with 100 ml of labeling buffer (10 mM HEPES, 140 mM NaCl, 5 mM CaCl 2 , 0.5 mg. propidium iodide and 1 ml annexinV-fluos (Roche Applied Science, Indianapolis, IN, USA), and incubated at 41C for 20 min. Labeling buffer was removed and the cells were resuspended in 400 ml of binding buffer (10 mM HEPES, 140 mM NaCl and 5 mM CaCl 2 ) Cells were immediately analyzed using a FACScan flow cytometer (Becton Dickenson, San Jose, CA, USA).
Flow-cytometric measurement of caspase activity
Caspase-3 and capase-9 activity was measured using the Apo Logixt Carboxyfluorescein Caspase (Cell Technology Inc., Minneapolis, MN, USA) detection kit with slight modification of the manufacturer's protocol. Collected cells were labeled by adding 10 ml of the FAM-peptide-FMK (caspase inhibitor) working dilution and incubating the cells at 371C for 1 h. Cells were washed twice with PBS þ 0.5% BSA and resuspended in 400 ml of PBS. Analysis was performed using a FACScan flow cytometer with Cell Quest Software (Becton Dickenson, San Jose, CA, USA).
Thymidine incorporation assays
Cells were seeded in 96-well plates (Corning, Corning, NY, USA) for 24 h. The cells were incubated under the various culture conditions and [
3 H]-thymidine (6.7 Ci/mmol)(NEN, Boston, MA, USA) was added for the last 6 h. Cells were harvested and transferred onto filter mats and assayed with a scintillation counter.
Results
The generation of FD/IGF-1R cells has been reported previously. 16 These cells exhibit loss of IL-3 dependence upon culture with IGF-1 or supraphysiological concentrations of insulin, indicating that IGF-1R signaling is sufficient to promote growth in the absence of IL-3, although they will still proliferate in the presence of IL-3 in the absence of IGF-1 or insulin. 16 
IGF-1R antibody blocks proliferation of FD/IGF-1R cells cultured with IGF-1
To test the antiproliferative effects of aIGF-1R antibody, A12, 6, 7 in the FD/IGF-1R system, FD/IGF-1R cells were cultured in IGF-1 or IGF-1 þ IL-3, with decreasing concentration of the A12 antibody. In parallel, the parental cell line, FDC-P1, was cultured in IL-3 or IL-3 þ IGF-1 with decreasing amounts of aIGF-1R. Thymidine incorporation, which measures DNA synthesis, was used as an indicator of cellular proliferation. Parental FDC-P1 cells, which express only low levels of IGF-1R, did not exhibit any inhibition of thymidine incorporation as a result of culture with the A12 antibody when IL-3 was present in the medium, with or without the addition of IGF-1 (Table 1a) . In contrast, thymidine incorporation in FD/IGF-1R cells was inhibited in the presence of aIGF-1R when the cells were cultured in IGF-1 alone (Table 1b) . The antiproliferative effect was determined to be dose-dependent with an IC 50 value of about 5 ng/ml. Similar to parental FDC-P1 cells, the addition of IL-3 to FD/IGF-1R cells in culture was sufficient to abrogate the antiproliferative effects of the A12 antibody, indicating that the cells can revert to their IL-3-dependent growth in the presence of IL-3, irrespective of IGF or IGF-1R status.
aIGF-1R antibody blocks entry into S phase in FD/IGF-1R cells (Table 2a ) and entered S phase (Table 2b) . On the contrary, cells cultured in IGF-1 and with aIGF-1R accumulated in G1 (Table 2a ) and failed to enter the S phase of the cell cycle (Table 2b ). This effect was most pronounced 2 days after the addition of aIGF-1R MoAb to the cultures. Consistent with the proliferation results, addition of IL-3 to the cultures exerted a dominant effect on cell cycle, irrespective of IGF-1R status, effecting entry into S phase (Table 2b ).
Expression of cell cycle regulatory proteins p21
Cip1 and p27 Kip1 17-19 These cells were used as a control as they are another example of a cell line that is conditionally transformed to grow in response to an activated tyrosine kinase receptor. aIGF-1R treatment had no apoptotic effect on FDC-P1 cells cultured in IL-3 or FD/v-ErbB:ER cells cultured with b-estradiol demonstrating the selectivity of this agent for the IGF-1R (Figure 2 ). In contrast, FD/IGF-1R cells cultured with IGF-1 exhibited a robust increase in apoptotic events upon the inclusion of aIGF-1R MoAb, even at low concentrations (1 ng/ ml). Maximum apoptotic events were observed at 10 ng/ml aIGF-1R MoAb and higher (Figures 2 and 3) .
A flow-cytometric assay was employed to measure activation of caspase-3 and caspase-9. Treatment of the FD/IGF-1R cells with IGF-1 and aIGF-1R MoAb resulted in the detection of activated (cleaved) forms of caspase-3 and caspase-9. These results are presented graphically in Figure 6 . The lowest levels of activated caspase-3 and caspase-9 were detected in cells cultured with IL-3. This suggests that IL-3 is exerting its prosurvival effects through the activation of separate survival pathways rather than blocking the activation of aIGF-1R-induced apoptotic pathways.
Treatment with aIGF-1R A12 antibody results in reduced levels of IGF-1R
To determine if induction of apoptosis by A12 antibody treatment correlated with loss of IGF-1R surface expression, FD/IGF-1R cells were treated with IGF-1 or IL-3 or both in the presence and/or absence of IGF-1R MoAb for 2 days. At 24 and 48 h, cells were analyzed for surface IGF-1R expression by fluorescence-activated cell sorting analysis using a mouse aIGF-1R antibody (Santa Cruz Biotechnology Inc., CA, USA) (Figure 4a) . Concurrently, cells were analyzed by annexinV/PI staining for apoptotic events (Figure 4b ). FD/IGF-1R cells cultured in the presence of IGF-1 exhibited both loss of surface IGF-1R expression and increased apoptotic events at A12 antibody concentrations of 3.5 ng/ml or higher. Cells cultured in IL-3 exhibited a loss of IGF-1R surface expression, but did not exhibit increased apoptotic events upon culture in the presence of A12 antibody. Insulin-like growth factor receptor-1 expression decreased after 24 h of A12 aIGF-1R treatment, but full effects on apoptosis were not observed until 48 h of treatment. In contrast, treatment of FD/IGF-1R cell with A12 aIGF-1R decreased IGF-1R expression, but did not increase apoptosis when the cells were treated with IL-3. (Figure 6b and c) . In contrast, when cells were treated with IL-3 and the aIGF-1R MoAb, reduced levels of phosphorylated MEK and ERK were not detected.
Signaling pathway inhibition synergizes with aIGF-1R MoAb treatment to promote apoptosis FD/IGF-1R cells were cultured in IGF-1 with increasing concentrations of A12 aIGF-1R MoAb and 0.5 nM of MEK, PI3K or mTOR inhibitors (Figure 7a ). As controls, the effects of increasing concentrations of each inhibitor alone were determined (Figure 7b ). aIGF-1R A12 MoAb concentrations of 1 ng/ ml and nanomolar amounts of either mTOR or MEK inhibitor were sufficient to promote greater than 90% apopoptic events (Figure 7a) . A similar observation was made with 1 ng/ml of A12 antibody and PI3K inhibitor. The effects of treatment with the aIGF-1R MoAb were presented previously in Figure 2 . Thus, combinatorial treatment of FD/IGF-1R cells with aIGF-1R A12 and small molecular weight signaling pathway inhibitors permitted the use of log-fold less antibody and inhibitor to promote rapid apoptosis of cells growing in response to IGF-1.
Discussion
Antibody-based cancer treatments have seen considerable success in selected classes of patients. 1, 2 In the present work, we sought to further investigate the mechanism of action of the aIGF-1R MoAb A12. Using an IGF-1/insulin-dependent hematopoietic cell line model, FD/IGF-1R, it was found that culture of the cells in IGF-1 along with the aIGF-1R A12 antibody resulted Figure 3 Flow-cytometric analysis of caspase activation following aIGF-1R A12 monoclonal antibody (MoAb) treatment. FD/IGF-1R cells were treated as described in Figure 2 . Activation of caspase-9 was measured using a flow-cytometric assay as described in Materials and methods. A graphical analysis of three experiments after 48 h of incubation is shown. In this study, we utilized a model leukemic cell line previously reported to rescue IL-3 dependence as a result of stable overexpression of human IGF-1R 16 in order to further assess the ability of the antagonist antibody A12 to inhibit selectively IGF-1R signaling and IGF-1R-dependent cellular responses. In this model, A12 inhibited IGF-1R-dependent mitogenesis and, consequently, initiation of cell proliferation with an IC 50 value of about 5 ng/ml. Indeed, prolonged treatment with antibody at a concentration as low as 1 ng/ml led to a near-complete elimination of the IGF-1R rescue effect in these cells, causing cells in culture to undergo apoptosis, similar to the effect of IL-3 withdrawal in the parent FDC-P1 cell line. Consistent with previous reports, we demonstrated that the inhibitory effect of A12 on IGF-1R was at least in part owing to direct receptor downmodulation following specific binding. 6, 7 The cell line used in this model was demonstrated to be conditionally dependent on IGF-1R, as IGF-1R transfectant cells were no longer responsive to A12 when IL-3 was present in the culture medium, regardless of presence or absence of IGF-1. This point is clinically relevant in that increased expression of IGF-1R in tumors cells is not a sufficient indication of dependence on this growth factor for tumor cell maintenance. Indeed, IGF-1R overexpression has been cited to be one mechanism by which breast cancer cells can become resistant to the Her2 inhibitor trastuzumab. 20 However, a recent study of clinical samples has documented that IGF-1R status alone is insufficient to predict resistance to trastuzumab therapy. 21 This does not suggest that IGF-1R is not relevant to cancer maintenance, simply that receptor positivity is not necessarily indicative of dependence in a tumor or tumor cell line. Lack of a correlation between EGFR positivity and response to cetuximab has also been observed in clinical testing. 22 The identification of biomarkers for determining response to targeted therapies will require more detailed investigation of the various intracellular signaling molecules and their dependence on, and redundancy in, the multiple growth factor cascades. In the near term, because it is probable that most tumors will be coordinately dependent on multiple growth factors for maintenance, the use of combinations of targeted therapies are likely to be most effective in controlling the growth of most types of tumor. To this end, recent studies have suggested that targeting more than one growth factor pathway may provide greater tumor growth control than single-agent therapy. 8 In this study, we provide evidence that the use of aIGF-1R in combination with certain specific signaling pathway inhibitors profoundly lowered the effective dose needed for each reagent to promote apoptosis. In addition to likely providing greater response rates, such combinations may also require lower dose of reagents compared to single agent, and therefore may likely result in reduced side effects and toxicity on normal cells in the patient.
In summary, we report that treatment with aIGF-1R A12 MoAb alone is sufficient to promote apoptosis in an IGF-1-/ insulin conditionally dependent hematopoietic cell line model. Moreover, the effective doses of aIGF-1R MoAb could be considerably lowered in the presence of small molecule inhibitors of signaling pathways. These data presented herein indicate that there may be considerable advantage to the use of the A12 aIGF-1R MoAb in combination with other signaling pathway inhibitors. These data will add in the subsequent design of novel therapeutic treatment strategies for a variety of different cancers.
